Regional and temporal changes in cardiovascular responses to norepinephrine and vasopressin during continuous infusion of lipopolysaccharide in conscious rats

British Journal of Anaesthesia

Volumn 93, Issue 3, 2004, Pages 400-407

  Bennett, T ^a   Mahajan, R P ^b   March, J E ^a   Kemp, P A ^a   Gardiner, Sheila M ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Blood, regional haemodynamics; Complications, endotoxaemia; Model, rat; Sympathetic nervous system, norepinephrine; Sympathetic nervous system, ornithine 8 vasopressin

Indexed keywords

ARGIPRESSIN; ATIPAMEZOLE; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; FENTANYL; FENTANYL CITRATE; MEDETOMIDINE; NALBUPHINE; NORADRENALIN BITARTRATE; SODIUM CHLORIDE; LIPOPOLYSACCHARIDE; NORADRENALIN; VASOCONSTRICTOR AGENT; VASOPRESSIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRADYCARDIA; CARDIOVASCULAR RESPONSE; CONSCIOUSNESS; CONTINUOUS INFUSION; CONTROLLED STUDY; DOPPLER FLOWMETRY; DOSE RESPONSE; HEMODYNAMICS; KIDNEY BLOOD FLOW; LIMB BLOOD FLOW; LOW DRUG DOSE; MALE; MESENTERY BLOOD FLOW; NONHUMAN; PRIORITY JOURNAL; RAT; SEPTIC SHOCK; VASOCONSTRICTION; ANIMAL; BLOOD PRESSURE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG EFFECT; ENDOTOXEMIA; HEART RATE; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; VASCULAR RESISTANCE;

ANIMALS; BLOOD PRESSURE; ENDOTOXEMIA; HEART RATE; HEMODYNAMIC PROCESSES; LIPOPOLYSACCHARIDES; MALE; NOREPINEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR RESISTANCE; VASOCONSTRICTOR AGENTS; VASOPRESSINS;

EID: 4444282926     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/aeh214     Document Type: Article

References (33)

1. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001; 345: 588-95
2. Dünser MW, Wenzel V, Mayr AJ, Hasibeder WR. Management of vasodilatory shock. Defining a role of arginine vasopressin. Drugs 2003; 63: 237-56
3. Sun Q, Dimopoulos G, Nguyen DN, et al. Low-dose vasopressin in the treatment of septic shock in sheep. Am J Respir Crit Care Med 2003; 168: 481-6
4. Holmes CL, Patel BM, Russell JA, Walley KR. Physiology of vasopressin relevant to management of septic shock. Chest 2001; 120: 989-1002
5. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilatation of septic shock. Circulation 1997; 95: 1122-5
6. Sharshar T, Blanchard A, Paillard M, Raphael JC, Gajdos P, Annane D. Circulating vasopressin levels in septic shock. Crit Care Med 2003; 31: 1752-8
7. Landry DW, Levin HR, Gallant EM, et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 1997; 25: 1279-82
8. Dünser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock. A prospective, randomised, controlled study. Circulation 2003; 107: 2313-9
9. O'Brien A, Clapp L, Singer M. Terlipressin for norepinephrine-resistant septic shock. Lancet 2002; 359: 1209-10
10. O'Brien AJ, Stidwill R, Clapp LH, Singer M. In vivo and in vitro differences in responses to catecholamines and vasopressin in rat models of LPS. Intensive Care Med 2002; 28 (Suppl.): S96
11. Guzman JA, Rosado AE, Kruse JA. Vasopressin vs norepinephrine in endotoxic shock: systemic, renal, and splanchnic hemodynamic and oxygen transport effects. J Appl Physiol 2003; 95: 803-9
12. Waller J, Gardiner SM, Bennett T. Regional haemodynamic responses to acetylcholine, methoxamine, salbutamol and bradykinin during lipopolysaccharide infusion in conscious rats. Br J Pharmacol 1994; 112: 1057-64
13. Tarpey SB, Bennett T, Randall MD, Gardiner SM. Differential effects of endotoxaemia on pressor and vasoconstrictor actions of angiotensin II and arginine vasopressin in conscious rats. Br J Pharmacol 1998; 123: 1367-74
14. Gardiner SM, Kemp PA, March JE, Bennett T. Cardiac and regional haemodynamics, inducible nitric oxide synthase (NOS) activity, and the effects of NOS inhibitors in conscious, endotoxaemic rats. Br J Pharmacol 1995; 116: 2005-16
15. March JE, Kemp PA, Mahajan R, Bennett T. Haemodynamic effects of noradrenaline (NA) infusion in conscious rats treated with lipopolysaccharide (LPS). Proceedings of the British Pharmacological Society at http://www.pa2online.org/VolIIssue3abst024P.html
16. Blair R, Fishman B, Amit Z, Weeks JR. A simple double-channel swivel for infusions of fluids into unrestrained animals. Pharmacol Biochem Behav 1980; 12: 463-6
17. Farmer MR, Roberts RE, Gardiner SM, Ralevic V. Effects of in vivo lipopolysaccharide infusion on vasoconstrictor function of rat isolated mesentery, kidney, and aorta. J Pharmacol Exp Ther 2003; 306: 538-45
18. Theodorsson-Norheim E. Friedman and Quade tests. BASIC computer program to perform non-parametric two-way analysis of variance and multiple comparisons on ranks of several related samples. Comput Biol Med 1987; 17: 85-99
19. 1-adrenergic receptor expression during endotoxemia. Crit Care Med 2003; 31: 566-71
20. Takakura K, Taniguchi T, Muramatsu I, Takeuchi K, Fukuda S. Modification of alpha 1-adrenoceptors by peroxynitrite as a possible mechanism of systemic hypotension in sepsis. Crit Care Med 2002; 30: 894-9
21. Pleiner J, Heere-Ress E, Langenberger H, et al. Adrenoceptor hyporeactivity is responsible for Escherichia coli endotoxin-induced acute vascular dysfunction in humans. Arterioscler Thromb Vasc Biol 2002; 22: 95-100
22. Gardiner SM, Kemp PA, March JE, Bennett T. Temporal differences between the involvement of angiotensin II and endothelin in the cardiovascular responses to endotoxaemia in conscious rats. Br J Pharmacol 1996; 119: 1619-27
23. Schaller MD, Waeber B, Nussberger J, Brunner HR. Angiotensin II, vasopressin and sympathetic activity in conscious rats with endotoxemia. Am J Physiol 1985; 249: H1086-92
24. El-Armouche A, Zolk O, Rau T, Eschenhagen T. Inhibitory G-proteins and their role in desensitization of the adenylyl cyclase pathway in heart failure. Cardiovasc Res 2003; 60: 478-87
25. Dünser MW, Mayr AJ, Ulmer H, et al. The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis. Anesth Analg 2001; 93: 7-13
26. Martikainen TJ, Tenhunen JJ, Uusaro A, Ruokonen E. The effects of vasopressin on systemic and splanchnic hemodynamics and metabolism in endotoxin shock. Anesth Analg 2003; 97: 1756-63
27. Asfar P, Pierrot M, Veal N, et al. Low-dose terlipressin improves systemic and splanchnic hemodynamics in fluid-challenged endotoxic rats. Crit Care Med 2003; 31: 215-20
28. Morelli A, Rocco M, Conti G, et al. Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock. Intensive Care Med 2004; 30: 597-604
29. Klinzing S, Simon M, Reinhart K, Bredle DL, Meier-Hellmann A. High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med 2003; 31: 2646-50
30. Bucher M, Hobbhahn J, Taeger K, Kurtz A. Cytokine-mediated downregulation of vasopressin VIA receptors during acute endotoxemia in rats. Am J Physiol 2001; 282: R979-84
31. Waller J, Gardiner SM, Jose J, Bennett T. Lack of effect of TNF-antibodies on the cardiovascular sequelae of lipopolysaccharide infusion in conscious rats. Br J Pharmacol 1995; 116: 2487-95
32. Bennett T, Gardiner SM. Influence of exogenous vasopressin on baroreflex mechanisms. Clin Sci 1986; 70: 307-15
33. Gardiner SM, Bennett T. Endogenous vasopressin and baroreflex mechanisms. Brain Res Rev 1986; 11: 317-34